Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the Shield™ by Guardant blood-based screening test is now widely accessible for physician order through ...
Colorectal cancer is the second-leading cause of cancer-related death in the U.S., even though it is highly treatable if caught early.2 The American Cancer Society estimates that more than 150,000 ...
Active-duty service members and eligible family members now have access to blood test for colorectal cancer screening with no copay Shield is the first and only blood test approved by the FDA as a ...
New FDA-approved screening options make colorectal cancer detection easier than ever, with 91% survival rates when caught ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of Shield Across America ...
PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (GH), a leading precision oncology company, today announced new real-world data published in Current Medical Research and Opinion finding ...
Screening for the second leading cause of cancer deaths just got a bit easier. The U.S. Food and Drug Administration (FDA) announced the approval of a new blood test for colorectal cancer (CRC).
It’s good news in the fight against colorectal cancer: A new test can detect the disease with a simple blood draw. But don’t cancel your colonoscopy just yet — that old standby is still more reliable ...
Colorectal cancer is one of the cancers where, if found early, it has a 91% chance of survival for the patient. If you find ...
To screen for colon and rectal cancers, most people have colonoscopies, which can feel invasive and require anesthesia, or they may take an at-home stool test, which can be more convenient but also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results